- Plastic Reconstructive Surgery
- Gastrointestinal Surgery
- Wound Care
- Cardiovascular Surgery
- Minimally Invasive Surgery
- Economic Benefits
- Novadaq Commercial
Enabling surgeons with clinically-relevant, innovative fluorescence imaging solutions to enhance the lives of patients and their surgeons, while reducing health care costs, is Novadaq’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to harmful ionizing radiation or contrast dye toxicity. More than 75 peer-reviewed publications demonstrate that the use of SPY during complex surgery, leads to fewer post-operative complications and lower hospital costs.
The SPY Imaging System is United States Food and Drug Administration (“FDA”) 510(k) cleared for use for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. Our unique business model of partnering with market-leading companies to drive adoption of our fluorescence imaging technology, while building our own commercial infrastructure is the cornerstone of our corporate strategy for growth.
Novadaq is traded on the NASDAQ Stock Exchange (Sym: NVDQ) and the TSX (Sym: NDQ).